13 October 2017
EMA/PDCO/675083/2017
Inspections, Human Medicines Pharmacovigilance and Committees Division

Paediatric Committee (PDCO)

Minutes of the meeting on 10-13 October 2017

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

10 October 2017, 14:00- 19:00, room 3A

11 October 2017, 08:30- 19:00, room 3A

12 October 2017, 08:30- 19:00, room 3A

13 October 2017, 08:30- 13:00, room 3A

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions 7

1.1. Welcome and declarations of interest of members, alternates and experts 7

1.2. Adoption of agenda 7

1.3. Adoption of the minutes 7

2. Opinions 7

2.1. Opinions on Products 7

2.1.1. Omega-3-carboxylic acids - EMEA-001865-PIP02-16 7

2.1.2. Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA that is covalently linked to a ligand containing three N-acetylgalactosamine residues - Orphan - EMEA-002079-PIP01-16 8

2.1.3. Iron hydroxyethyl amylopectin heptonate - EMEA-002094-PIP01-16 8

2.1.4. Emapalumab - Orphan - EMEA-002031-PIP01-16 8

2.1.5. Recombinant humanised IgG4 monoclonal antibody against MSRV-Envelope protein (GNbAC1) - EMEA-002127-PIP01-17 9

2.1.6. Ruxolitinib phosphate - EMEA-000901-PIP03-16 9

2.1.7. Allopregnanolone - EMEA-002051-PIP02-16 9

2.1.8. N. meningitidis serogroup W polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup Y polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup C polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup A polysaccharide conjugated to tetanus toxoid - EMEA-001930-PIP01-16 9

2.1.9. Ezetimibe / atorvastatin - EMEA-002207-PIP01-17 10

2.1.10. Vonapanitase - Orphan - EMEA-002195-PIP01-17 10

2.1.11. Opicinumab - EMEA-002194-PIP01-17 10

2.1.12. Resminostat - Orphan - EMEA-002211-PIP01-17 11

2.1.13. Soluble human T cell receptor (TCR) directed against the glycoprotein 100 (gp100) melanoma antigen, linked to the single-chain variable fragment (ScFv) domain of the anti-cluster of differentiation 3 (CD3) antibody - EMEA-002197-PIP01-17 11

2.1.14. Tolonium chloride - EMEA-002170-PIP01-17 12

2.1.15. Human Neutrophil Elastase Inhibitor - EMEA-002196-PIP01-17 12

2.2. Opinions on Compliance Check 12

2.2.1. Turoctocog alfa pegol - EMEA-C1-001174-PIP02-12-M02 12

2.2.2. Treosulfan - EMEA-C1-000883-PIP01-10-M04 13

2.2.3. Rivaroxaban - EMEA-C4-000430-PIP01-08-M10 13

2.2.4. Entolimod - EMEA-C2-002020-PIP01-16-M01 13

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan 14

2.3.1. Tolvaptan - EMEA-001231-PIP02-13-M05 14

2.3.2. Teduglutide ([gly2] recombinant human glucagon-like peptide) - Orphan - EMEA-000482-PIP01-08-M04 14

2.3.3. Fc- and CDR-modified humanised monoclonal antibody against C5 - Orphan - EMEA-002077-PIP01-16-M01 14
2.3.4. Sarilumab - EMEA-001045-PIP01-10-M01 15
2.3.5. Secukinumab - EMEA-000380-PIP01-08-M04 15
2.3.6. Upadacitinib - EMEA-001741-PIP01-14-M01 16
2.3.7. Adalimumab - EMEA-000366-PIP02-09-M05 16
2.3.8. Lumicitabine - EMEA-001758-PIP01-15-M02 16
2.3.9. Telavancin hydrochloride - EMEA-000239-PIP01-08-M03 17
2.3.10. Thrombomodulin alfa - EMEA-001363-PIP01-12-M01 17
2.3.11. Bumetanide - EMEA-001303-PIP01-12-M02 17
2.3.12. Eculizumab - Orphan - EMEA-000876-PIP03-14-M01 18
2.3.13. Lacosamide - EMEA-000402-PIP03-17-M01 18
2.3.14. Ozanimod - EMEA-001710-PIP02-14-M02 19
2.3.15. Avelumab - Orphan - EMEA-001849-PIP02-15-M01 19
2.3.16. Naltrexone HCl / Bupropion HCl - EMEA-001373-PIP01-12-M03 20
2.3.17. Palovarotene - Orphan - EMEA-001662-PIP01-14-M01 20
2.3.18. Tapentadol - EMEA-000018-PIP01-07-M14 20
2.3.19. Mirabegron - EMEA-000597-PIP02-10-M06 21
2.3.20. Sotagliflozin - EMEA-001517-PIP02-14-M02 21
2.3.21. Lubiprostone - EMEA-000245-PIP01-08-M04 21
2.3.22. Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1) - EMEA-002068-PIP01-16-M01 22
2.4. Opinions on Re-examinations 22
2.5. Finalisation and adoption of opinions 22
3. Discussion of applications 22
3.1. Discussions on Products D90-D60-D30 23
3.1.1. Brazikumab - EMEA-001929-PIP01-16 23
3.1.2. Susoctocog alfa - EMEA-000753-PIP02-16 23
3.1.3. Risankizumab - EMEA-001776-PIP02-17 23
3.1.4. Trazodone hydrochloride - EMEA-002142-PIP01-17 23
3.1.5. Carotuximab - Orphan - EMEA-002138-PIP01-17 23
3.1.6. fully human monoclonal antibody (mAb) directed against the human PD-1 receptor - EMEA-002007-PIP02-17 23
3.1.7. Vosoritide - Orphan - EMEA-002033-PIP01-16 24
3.1.8. Bupivacaine - EMEA-000877-PIP02-16 24
3.1.9. Formoterol fumarate / glycopyrronium bromide / budesonide - EMEA-002063-PIP01-16 24
3.1.10. EMEA-002216-PIP01-17 24

3.1.11. EMEA-002208-PIP01-17 24
3.1.12. Inclisiran sodium - EMEA-002214-PIP01-17 25
3.1.13. Anti-Mucosal Addressin Cell Adhesion Molecule Antibody - EMEA-002218-PIP01-17 25
3.1.14. Ibrutinib - Orphan - EMEA-001397-PIP04-17 25
3.1.15. Branaplam - EMEA-002204-PIP01-17 25
3.1.16. Glasdegib maleate - EMEA-002199-PIP01-17 25
3.1.17. Isatuximab - Orphan - EMEA-002205-PIP01-17 26
3.1.18. Autologous cartilage derived cultured chondrocytes - EMEA-002217-PIP01-17 26
3.1.19. EMEA-001976-PIP01-16 26
3.1.20. Plant-derived Quadrivalent VLP Influenza vaccine - EMEA-002220-PIP01-17 26
3.1.21. EMEA-002215-PIP01-17 26
3.1.22. EMEA-001527-PIP02-17 26
3.1.23. Itacitinib - EMEA-002178-PIP01-17 27
3.1.24. Tedizolid phosphate - EMEA-001379-PIP02-17 27
3.1.25. Fremanezumab - EMEA-001877-PIP03-17 27
3.1.26. Setmelanotide - Orphan - EMEA-002209-PIP01-17 27
3.1.27. Afatinib - EMEA-001596-PIP02-17 27
3.1.28. Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide specific to the mRNA of the caspase 2 gene - EMEA-002224-PIP01-17 28
3.1.29. Fosnetupitant / palonosetron - EMEA-001198-PIP03-17 28
3.1.30. Sirolimus - Orphan - EMEA-002213-PIP01-17 28
3.1.31. EMEA-002160-PIP01-17 28
3.1.32. Clade C gp140 - EMEA-002221-PIP01-17 28
3.1.33. Mosaic gp140 / Clade C gp140 - EMEA-002161-PIP01-17 28
3.2. Discussions on Compliance Check 29
3.2.1. Avacopan - EMEA-C1-002023-PIP01-16-M01 29
3.2.2. Mepolizumab - EMEA-C-000069-PIP02-10-M08 29
3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan 29
3.3.1. Recombinant human glutamic acid decarboxylase (rhGAD65) - EMEA-000609-PIP01-09-M0129
3.3.2. Eluxadoline - EMEA-001579-PIP01-13-M02 29
3.3.3. Human coagulation factor X - Orphan - EMEA-000971-PIP01-10-M03 29
3.3.4. Avacopan - Orphan - EMEA-002023-PIP01-16-M02 30
3.3.5. Human normal immunoglobulin for subcutaneous administration - EMEA-001853-PIP01-15-M01 30
3.3.6. Bezlotoxumab - EMEA-001645-PIP01-14-M02 30
3.3.7. Ataluren - Orphan - EMEA-000115-PIP01-07-M09 30
3.3.8. Delta-9-tetrahydrocannabinol / Cannabidiol - EMEA-000181-PIP01-08-M04 30
3.3.9. Blinatumomab - Orphan - EMEA-000574-PIP02-12-M02 30
3.3.10. Ibrutinib - Orphan - EMEA-001397-PIP03-14-M03 31

3.3.11. Inotuzumb ozogamicin - Orphan - EMEA-001429-PIP01-13-M02 31
3.3.12. Human Thrombin / Human Fibrinogen - EMEA-001149-PIP01-11-M04 31
3.3.13. Lanadelumab - Orphan - EMEA-001864-PIP01-15-M01 31
3.3.14. Sildenafil - Orphan - EMEA-000671-PIP01-09-M09 31
3.3.15. Spheroids of human autologous matrix-associated chondrocytes - EMEA-001264-PIP01-12-M01 32
3.3.16. Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) (1/5) each - EMEA-000794-PIP01-09-M01 32
3.3.17. Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) and Secale cereale (Cultivated Rye) pollen (50/50) - EMEA-000792-PIP01-09-M01 32
3.3.18. Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of Phleum pratense pollen - EMEA-000795-PIP01-09-M01 32

4. Nominations 33

4.1. List of letters of intent received for submission of applications with start of procedure 3 January 2018 for Nomination of Rapporteur and Peer reviewer 33

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver. 33

4.3. Nominations for other activities 33

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction 33

6. Discussion on the applicability of class waivers 33

6.1. Discussions on the applicability of class waiver for products 33

6.1.1. Ribavirin - EMEA-16-2017 33

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver 34

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver 34

7.1.1. Rivaroxaban - EMEA-000430-PIP01-08-M10 34

8. Annual reports on deferrals 34

9. Organisational, regulatory and methodological matters 34

9.1. Mandate and organisation of the PDCO 34

9.2. Coordination with EMA Scientific Committees or CMDh-v 34

9.2.1. Committee for Medicinal Products for Human Use (CHMP) 34

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups 35

9.3.1. Non-clinical Working Group: D30 Products identified 35
9.3.2. Formulation Working Group 35
9.3.3. Reflection paper on the use of extrapolation in paediatric medicines development 35

9.3.4. Minutes - PCWP/HCPWP joint meeting held on 27-28 June 2017 35
9.3.5. Revision of the 'Guideline on recombinant and plasma-derived FVIII products' 35
9.4. Cooperation within the EU regulatory network 35
9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA) 35
9.5. Cooperation with International Regulators 36
9.5.1. ICH S11 and ICH S9 Questions and answers 36
9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee 36
9.7. PDCO work plan 36
9.7.1. Draft PDCO Work plan 2018 36
9.8. Planning and reporting 36
9.8.1. Report on the International Paul Ehrlich Seminar - standard allergen PIP 36

10. Any other business 37
10.1. AOB topic 37
10.1.1. Preparedness of the system and capacity increase 37

11. Breakout sessions 37
11.1.1. Paediatric oncology 37
11.1.2. Neonatology 37
11.1.3. Inventory 37

12. List of participants 38
13. Explanatory notes 42

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda was adopted with amendments.

1.3. Adoption of the minutes

The minutes of the September 2017 PDCO plenary meeting were adopted with amendments and will be published on the EMA website.

2. Opinions

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Omega-3-carboxylic acids - EMEA-001865-PIP02-16

AstraZeneca AB; Hypertriglyceridaemia or mixed dyslipidaemia to reduce the risk of atherosclerotic cardiovascular disease (ACVD), Mixed dyslipidaemia with persistent hypertriglyceridaemia.

Day 120 opinion

Cardiovascular Diseases

Summary of committee discussion:

The PDCO discussed this product again on 10-13 October 2017. The PDCO confirmed all the points discussed at day 90.

A positive Opinion was agreed at Day 120.

2.1.2. Synthetic double-stranded siRNA oligonucleotide directed against hydroxyacid oxidase 1 mRNA that is covalently linked to a ligand containing three N-acetylgalactosamine residues - Orphan - EMEA-002079-PIP01-16

Alnylam UK Limited; Treatment of Primary Hyperoxaluria Type 1

Day 120 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

The PDCO confirmed the outcome of the Day 90 A positive opinion was adopted for the treatment of hyperoxaluria for the entire paediatric population from birth to less than 18 years of age.

2.1.3. Iron hydroxyethyl amylopectin heptonate - EMEA-002094-PIP01-16

iron4u; Iron deficiency anemia., Iron deficiency.

Day 120 opinion

Haematology-Hemostaseology

Summary of committee discussion:

The PDCO confirmed the outcome of the discussion at Day 90 and adopted a positive opinion on a PIP for the treatment of iron deficiency or iron deficiency anaemia

2.1.4. Emapalumab - Orphan - EMEA-002031-PIP01-16

Novimmune B.V; Treatment of Haemophagocytic Lymphohistiocytosis

Day 120 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The applicant requested an oral explanation since he felt that not all issues were resolved in a clarification TC that took place between day 90 and day 120.

The Company and the PDCO discussed the outstanding points for this procedure.

The PDCO adopted a positive Opinion at day 120.

2.1.5. Recombinant humanised IgG4 monoclonal antibody against MSRV-Envelope protein (GNbAC1) - EMEA-002127-PIP01-17

GeNeuro SA; Treatment of Multiple Sclerosis / Treatment of patients from 10 to less than 18 years old with relapsing-remitting multiple sclerosis

Day 120 opinion

Neurology

Summary of committee discussion:

The applicant had provided satisfactory responses to the questions raised by the PDCO at Day 30. The committee adopted a positive opinion on this PIP for the treatment of children with multiple sclerosis.

2.1.6. Ruxolitinib phosphate - EMEA-000901-PIP03-16

Novartis Europharm Limited; Acute graft versus host disease / Treatment of acute Graft vs Host Disease (GvHD) after allogeneic hematopoietic stem cell transplantation (alloSCT) in paediatric patients aged 28 days and above.

Day 120 opinion

Oncology

Summary of committee discussion:

The PDCO adopted a positive opinion on the paediatric plan proposed by the applicant.

2.1.7. Allopregnanolone - EMEA-002051-PIP02-16

Sage Therapeutics Inc; Treatment of postpartum depression

Day 120 opinion

Psychiatry

Summary of committee discussion:

After the Day 90 discussion, a clarification TC was held with the applicant on 25 September 2017.
The PDCO adopted a positive opinion on the paediatric plan proposed by the applicant.

2.1.8. N. meningitidis serogroup W polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup Y polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup C polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup A polysaccharide conjugated to tetanus toxoid - EMEA-001930-PIP01-16

Sanofi Pasteur Inc.; Prevention of Meningococcal Disease

Day 120 opinion

Vaccines

Summary of committee discussion:

Based on the assessment of this application the PDCO agreed at their October 2017 meeting a PIP for N. meningitidis serogroup A polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup Y polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup W polysaccharide conjugated to tetanus toxoid / N. meningitidis serogroup C polysaccharide conjugated to tetanus toxoid for all subsets of the paediatric population (0 to 18 years of age) in the condition of Prevention of Meningococcal Disease with a deferral.

2.1.9. Ezetimibe / atorvastatin - EMEA-002207-PIP01-17

EGIS Pharmaceuticals PLC; treatment of hypercholesterolaemia

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

The committee's views expressed on day 30 were re-discussed and endorsed.
Based on the assessment of this application the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for ezetimibe / atorvastatin for all subsets of the paediatric population (0 to 18 years of age) in the condition of "treatment of hypercholesterolaemia" on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

2.1.10. Vonapanitase - Orphan - EMEA-002195-PIP01-17

Proteon Therapeutics Limited; prevention of arteriovenous fistula failure

Day 60 opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee including contributions of external expert(s), the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for vonapanitase for all subsets of the paediatric population (0 to less than18 years of age) in the condition of prevention of arteriovenous access dysfunction.

The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.11. Opicinumab - EMEA-002194-PIP01-17

Biogen Idec Limited; Treatment of Multiple Sclerosis

Day 60 opinion

Neurology

Summary of committee discussion:

The committee's views expressed on day 30 were re-discussed

Based on the assessment of this application the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for Opicinumab for all subsets of the paediatric population (0 to 18 years of age) in the condition of "treatment of multiple sclerosis" on the grounds that the specific medicinal product does not represent a significant therapeutic benefit.

2.1.12. Resminostat - Orphan - EMEA-002211-PIP01-17

4SC AG; Cutaneous T-Cell Lymphoma

Day 60 opinion

Oncology

Summary of committee discussion:

In the time between the Day 30 and the day 60 PDCO discussion the applicant provided additional information

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for resminostat for all subsets of the paediatric population (0 to 18 years of age) in the condition of Cutaneous T-Cell Lymphoma.

2.1.13. Soluble human T cell receptor (TCR) directed against the glycoprotein 100 (gp100) melanoma antigen, linked to the single-chain variable fragment (ScFv) domain of the anti-cluster of differentiation 3 (CD3) antibody - EMEA-002197-PIP01-17

Immunocore Ltd; Treatment of ocular melanoma

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO confirmed all the points discussed at day 30.

The PDCO agreed that the condition 'treatment of ocular melanoma' is acceptable.

The PDCO also agreed with the full waiver request, based on lack of expected significant therapeutic benefit, since studies are not feasible due to the rarity of uveal melanoma.

A positive Opinion was agreed for this product at day 60.

2.1.14. Tolonium chloride - EMEA-002170-PIP01-17

Cumdente GmbH; Dental and oral soft tissue infections

Day 60 opinion

Other

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the applicant's request for a waiver. The PDCO recommends granting a waiver for tolonium chloride for all subsets of the paediatric population (0 to 18 years of age) in the condition of dental and oral soft tissue infections.

2.1.15. Human Neutrophil Elastase Inhibitor - EMEA-002196-PIP01-17

Chiesi Farmaceutici S.p.A; Treatment of Non-Cystic Fibrosis Bronchiectasis

Day 60 opinion

Pneumology - Allergology

Summary of committee discussion:

The PDCO views expressed at day 30 were re-discussed and endorsed.
Based on the assessment of this application and on the mechanism of action , the PDCO does not support restriction of the condition to non-cystic-fibrosis bronchiectasis (NCFBE); instead, the condition should be “treatment of bronchiectasis. The committee does not agree with the applicant's request for a waiver. Consequently, the PDCO adopted an opinion refusing a product-specific waiver for Human Neutrophil Elastase Inhibitor for all subsets of the paediatric population (0 to 18 years of age) in the condition of “treatment of bronchiectasis”. A paediatric investigation plan should be submitted in the condition “treatment of bronchiectasis”

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

2.2.1. Turoctocog alfa pegol - EMEA-C1-001174-PIP02-12-M02

Novo Nordisk A/S; Treatment of hereditary Factor VIII deficiency

Day 60 letter

Haematology-Hemostaseology

Summary of committee discussion:

The completed studies were checked for compliance.

The PDCO discussed the completed studies and considered that these are compliant with the latest Agency's Decision (P/0142/2017 of 21.04.17).

The PDCO finalised on 11.10.17 this partially completed compliance procedure.

2.2.2. Treosulfan - EMEA-C1-000883-PIP01-10-M04

medac Gesellschaft für klinische Spezialpräparate mbH; Conditioning treatment prior to haematopoietic progenitor cell transplantation

Day 60 letter

Immunology-Rheumatology-Transplantation / Oncology

Summary of committee discussion:

The PDCO finalised on 13 October 2017 this compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date, in accordance with the latest Agency's Decision (P/0197/2017) of 14 July 2017.

2.2.3. Rivaroxaban - EMEA-C4-000430-PIP01-08-M10

Bayer AG; Treatment of thromboembolic events

Day 30 letter

Cardiovascular Diseases

Summary of committee discussion:

The PDCO discussed the completed studies and considered that these are compliant with the latest Agency's Decision (P/0194/2017) of 23 June 2017.

The PDCO finalised on 11.10.17 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.2.4. Entolimod - EMEA-C2-002020-PIP01-16-M01

TMC Pharma Services Ltd.; Treatment of acute Radiation Syndrome

Day 30 letter

Other

Summary of committee discussion:

The PDCO discussed the completed studies and considered that these are compliant with the latest Agency's Decision (P/0295/2017) of 29 October 2017.

The PDCO finalised on 13 October 2017 this partially completed compliance procedure and confirmed the compliance of all those studies contained in the agreed paediatric investigation plan that were to be completed until this date.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Tolvaptan - EMEA-001231-PIP02-13-M05

Otsuka Pharmaceutical Europe Ltd.; Polycystic Kidney Disease (PKD), Dilutional hyponatraemia / Treatment of chronic (>48 hours) dilutional hyponatraemia resistant to fluid restriction (i.e., euvolemic and hypervolemic hyponatremia) associated with heart failure, cirrhosis or SIADH., Treatment of progression of ADPKD, Treatment of progression of ARPKD

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

The PDCO noted the clarifications submitted by the applicant between Day 30 and Day 60. The outcome of the discussion at Day 30 was confirmed.

The PDCO therefore adopted an Opinion on the refusal of the modification of the agreed PIP as set in the Agency's latest decision (P/0294/2016 of 04 November 2016) and on the granting of a product specific waiver.
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.2. Teduglutide ([gly2] recombinant human glucagon-like peptide) - Orphan - EMEA-000482-PIP01-08-M04

Shire Pharmaceuticals Ireland Limited; Treatment of Short Bowel Syndrome

Day 60 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

The PDCO discussed this application on D60. The applicant's responses to the D30 issues were acknowledged.

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0245/2015 of 30 October 2015).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.3. Fc- and CDR-modified humanised monoclonal antibody against C5 - Orphan - EMEA-002077-PIP01-16-M01

Alexion Europe SAS; Treatment of Paroxysmal Nocturnal Haemoglobinuria

Day 60 opinion

Haematology-Hemostaseology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted, with some additions.

The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0199/2017 of 14 July 2017).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.4. Sarilumab - EMEA-001045-PIP01-10-M01

sanofi-aventis recherche et développement; Treatment of chronic idiopathic arthritis (including rheumatoid arthrtis, spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The applicant had provided all requested clarifications prior to the Day 60 discussion. The PDCO agreed with the applicant's justification for the proposed changes to the PIP . A positive opinion was adopted.

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0067/2013 of 26/03/2013).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.5. Secukinumab - EMEA-000380-PIP01-08-M04

Novartis Europharm Ltd; Psoriasis / Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0140/2015 of 10 July 2015).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.6. Upadacitinib - EMEA-001741-PIP01-14-M01

AbbVie Ltd; Treatment of Chronic Idiopathic Arthritis / Treatment of Juvenile Idiopathic Arthritis

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO discussed the clarification received from the applicant

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0288/2015 of 9/10/2015).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.7. Adalimumab - EMEA-000366-PIP02-09-M05

AbbVie Limited; Ulcerative Colitis / Treatment of Moderate to severe ulcerative colitis

Day 60 opinion

Immunology-Rheumatology-Transplantation / Ophthalmology / Dermatology / Gastroenterology-Hepatology

Summary of committee discussion:

The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0131/2015 of 12 June 2015).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.8. Lumicitabine - EMEA-001758-PIP01-15-M02

Janssen-Cilag International NV; Treatment of lower respiratory tract disease caused by human respiratory syncytial virus

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0029/2017 of 27 January 2017).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.9. Telavancin hydrochloride - EMEA-000239-PIP01-08-M03

Theravance Biopharma Ireland Ltd.; Nosocomial Pneumonia (NP)

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

At their October 2017 meeting the PDCO noted the responses of the applicant to the comments raised at D30.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0318/2016 of 2/12/2016).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.10. Thrombomodulin alfa - EMEA-001363-PIP01-12-M01

Asahi Kasei Pharma America Corporation; Treatment of sepsis / Treatment of patients with severe sepsis (respiratory failure and/or septic shock) with coagulopathy

Day 60 opinion

Infectious Diseases

Summary of committee discussion:

The PDCO was briefed on a teleconference between the rapporteur team and the applicant in the time between Day 30 and Day 60
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes were acceptable. The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.11. Bumetanide - EMEA-001303-PIP01-12-M02

Les Laboratoires Servier; Treatment of Autism Spectrum Disorder

Day 60 opinion

Neurology

Summary of committee discussion:

The Committee reviewed the application including the new information since Day 30 and the assessors' comments, and found most of the proposed modifications acceptable. the PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision. The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.12. Eculizumab - Orphan - EMEA-000876-PIP03-14-M01

Alexion Europe SAS; Treatment of Relapsing Neuromyelitis Optica Spectrum Disorders in the paediatric population

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0356/2016 of 21 December 2016).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.13. Lacosamide - EMEA-000402-PIP03-17-M01

UCB Pharma S.A.; Treatment of Generalized Epilepsy and Epilepsy Syndromes: Epilepsy - generalized idiopathic epilepsy and epilepsy syndromes [G40.3] Epilepsy - Other generalized epilepsy and epileptic syndromes [G40.4] / Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in pediatric patients with idiopathic generalized epilepsy (IGE)(4 years to <18 years), Adjunctive therapy in the treatment of epileptic syndromes associated with generalized seizures in pediatric patients with epilepsy birth to <18 years (specific epileptic syndrome(s) to be based on future clinical development further to exploratory study results)

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision.

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.14. Ozanimod - EMEA-001710-PIP02-14-M02

Celgene Europe Limited; Treatment of multiple sclerosis / Treatment of relapsing remitting forms of multiple sclerosis

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0161/2017 of 30 June 2017).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.15. Avelumab - Orphan - EMEA-001849-PIP02-15-M01

Merck KGaA; Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms) / Treatment of malignant neoplasms of lymphoid tissue / Treatment of malignant neoplasms of the central nervous system

Day 60 opinion

Oncology

Summary of committee discussion:

The PDCO re-discussed the request modification for avelumab also taking into account the clarifications and the comments on the draft opinion received by the applicant after the D30 discussion.

In conclusion, based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0071/2017 of 17 March 2017) for the condition 'treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)' and the two added conditions 'Treatment of malignant neoplasms of lymphoid tissue' and 'treatment of malignant neoplasms of the central nervous system'.

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.16. Naltrexone HCl / Bupropion HCl - EMEA-001373-PIP01-12-M03

Orexigen Therapeutics Ireland Limited; Treatment of obesity

Day 60 opinion

Other

Summary of committee discussion:

Some of the elements discussed at D30 have been resolved.

The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision.

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.17. Palovarotene - Orphan - EMEA-001662-PIP01-14-M01

Clementia Pharmaceuticals Inc.; Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Day 60 opinion

Other

Summary of committee discussion:

The PDCO re-discussed this procedure at day 60 on 10-13 October 2017.
The Committee confirmed all the points raised during the day 30 discussion.

The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision P/0127/2015 of 5 June 2015).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.18. Tapentadol - EMEA-000018-PIP01-07-M14

Grünenthal GmbH; Treatment of acute pain

Day 60 opinion

Pain

Summary of committee discussion:

The PDCO's view expressed at day 30 was re-discussed and endorsed.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0120/2017 of 5 May 2017).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO

Opinion.

2.3.19. Mirabegron - EMEA-000597-PIP02-10-M06

Astellas Pharma Europe B.V.; Treatment of idiopathic overactive bladder / Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome

Day 60 opinion

Uro-nephrology

Summary of committee discussion:

The PDCO confirmed the outcome of the Day 30 discussion. Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could not be accepted.

The PDCO therefore adopted a negative Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0287/2016 of 04 November 2016).

2.3.20. Sotagliflozin - EMEA-001517-PIP02-14-M02

sanofi-aventis R&D; Treatment of type 1 diabetes mellitus

Day 30 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

The PDCO discussed the modification request on 11 October 2017.

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. It was also noted that this is a retrospective request for modification however without any impact on the completion of the PIP.

The Committee agreed to adopt the opinion (on the modification of the agreed PIP as set in the Agency's latest decision (P/0227/2017) at D30.

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.21. Lubiprostone - EMEA-000245-PIP01-08-M04

Sucampo AG; chronic idiopathic constipation

Day 30 opinion

Gastroenterology-Hepatology

Summary of committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed

paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0241/2016 of 9 September 2016).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.22. Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1) - EMEA-002068-PIP01-16-M01

Seqirus UK Limited; Prevention of influenza

Day 30 opinion

Vaccines

Summary of committee discussion:

The PDCO discussed the modification request on 10 October 2017.
Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0209/2017 of 9 August 2017).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.4. Opinions on Re-examinations

No items.

2.5. Finalisation and adoption of opinions

3. Discussion of applications

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Brazikumab - EMEA-001929-PIP01-16

Crohn's disease, Ulcerative colitis

Day 90 discussion

Gastroenterology-Hepatology

3.1.2. Susoctocog alfa - EMEA-000753-PIP02-16

Congenital haemophilia A with antibodies (inhibitors) to human factor VIII / Peri-operative management in patients with congenital haemophilia A with antibodies (inhibitors) to human FVIII

Day 90 discussion

Haematology-Hemostaseology

3.1.3. Risankizumab - EMEA-001776-PIP02-17

Chronic Idiopathic Arthritis

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.4. Trazodone hydrochloride - EMEA-002142-PIP01-17

Treatment of insomnia

Day 90 discussion

Neurology

3.1.5. Carotuximab - Orphan - EMEA-002138-PIP01-17

TRACON Pharma Limited; Treatment of soft tissue sarcoma

Day 90 discussion

Oncology

3.1.6. fully human monoclonal antibody (mAb) directed against the human PD-1 receptor - EMEA-002007-PIP02-17

Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue) / Treatment of newly diagnosed diffuse intrinsic pontine gliomas (DIPG), newly diagnosed and recurrent high-grade gliomas (HGG)

Day 90 discussion

Oncology

3.1.7. Vosoritide - Orphan - EMEA-002033-PIP01-16

BioMarin International Limited; Treatment of achondroplasia

Day 90 discussion

Other

3.1.8. Bupivacaine - EMEA-000877-PIP02-16

postsurgical analgesia

Day 90 discussion

Pain

3.1.9. Formoterol fumarate / glycopyrronium bromide / budesonide - EMEA-002063-PIP01-16

Asthma / For the regular treatment of asthma in children 6 to 11 years of age where use of a triple combination medicinal product (ICS, LAMA and LABA) is appropriate: • patients not adequately controlled with ICS and another controller such as a LABA or LAMA

Day 90 discussion

Pneumology - Allergology

3.1.10. EMEA-002216-PIP01-17

Treatment of Atopic Dermatitis

Day 60 discussion

Dermatology

3.1.11. EMEA-002208-PIP01-17

Treatment of psoriasis, Treatment of Crohn's disease, Treatment of ulcerative colitis / Treatment of moderate to severely active Crohn's disease in paediatric patients aged 2 to less than 18 years of age, Treatment of moderate to severely active ulcerative colitis in paediatric patients aged 2 to less than 18 years of age, Treatment of moderate-to-severe plaque psoriasis in paediatric patients aged 6 to less than 18 years of age.

Day 60 discussion

Dermatology / Gastroenterology-Hepatology

3.1.12. Inclisiran sodium - EMEA-002214-PIP01-17

Treatment of elevated cholesterol / Inclisiran is indicated to lower LDL-C in adults and children aged 11 years old and older with heterozygous familial hypercholesterolemia in combination with other lipid lowering therapies., Inclisiran is indicated to lower LDL-C in adults and children aged 11 years old and older with homozygous familial hypercholesterolemia in combination with other lipid lowering therapies.

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.13. Anti-Mucosal Addressin Cell Adhesion Molecule Antibody - EMEA-002218-PIP01-17

Treatment of Ulcerative Colitis, Treatment of Crohn's Disease / Treatment of moderate to severe active Crohn's Disease, Treatment of moderate to severe active Ulcerative Colitis

Day 60 discussion

Gastroenterology-Hepatology

3.1.14. Ibrutinib - Orphan - EMEA-001397-PIP04-17

Janssen-Cilag International N.V.; Treatment of cGVHD / indicated for the treatment of cGVHD in children 1 year of age and older.

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.15. Branaplam - EMEA-002204-PIP01-17

Spinal Muscular Atrophy

Day 60 discussion

Neurology

3.1.16. Glasdegib maleate - EMEA-002199-PIP01-17

Treatment of acute myeloid leukaemia (AML) / • Glasdegib as monotherapy for prevention of AML relapse in children aged 2 years up to <18 years with high risk for relapse post-alloSCT; • Glasdegib in combination with FLAG/DNX as reinduction treatment of R/R AML in children aged 2 years up to <18 years, followed by consolidation therapy with or without SCT, and finally single-agent glasdegib post-consolidation.

Day 60 discussion

Oncology

3.1.17. Isatuximab - Orphan - EMEA-002205-PIP01-17

Sanofi-Aventis Recherche & Développement; Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue / Treatment of relapsed, refractory acute lymphoblastic leukemia in combination with standard treatment in paediatric patients with no more than one prior salvage therapy, Treatment of relapsed, refractory acute myeloblastic leukemia in combination with standard treatment in paediatric patients with no more than one prior salvage therapy

Day 60 discussion

Oncology

3.1.18. Autologous cartilage derived cultured chondrocytes - EMEA-002217-PIP01-17

Treatment of cartilage disorders

Day 60 discussion

Other

3.1.19. EMEA-001976-PIP01-16

Asthma / Once-daily maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older (and in age 5-11) where use of a maintenance anti-inflammatory medication is appropriate

Day 60 discussion

Pneumology - Allergology

3.1.20. Plant-derived Quadrivalent VLP Influenza vaccine - EMEA-002220-PIP01-17

Medicago Inc.; prophylaxis of seasonal influenza / For active immunization of persons six months of age and older for the prevention of disease caused by influenza A subtype viruses and type B viruses covered by the vaccine.

Day 60 discussion

Vaccines

3.1.21. EMEA-002215-PIP01-17

Disease caused by Streptococcus pneumoniae

Day 60 discussion

Vaccines

3.1.22. EMEA-001527-PIP02-17

Treatment of obesity

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.23. Itacitinib - EMEA-002178-PIP01-17

Treatment of acute Graft versus Host Disease (D89.810, ICD-10-CM) / Treatment of steroid naïve paediatric population with acute graft versus host disease after allogeneic hematopoietic stem cell transplantation

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.24. Tedizolid phosphate - EMEA-001379-PIP02-17

Treatment of Gram-positive bacterial pneumonia

Day 30 discussion

Infectious Diseases

3.1.25. Fremanezumab - EMEA-001877-PIP03-17

Prevention of cluster headache

Day 30 discussion

Neurology

3.1.26. Setmelanotide - Orphan - EMEA-002209-PIP01-17

Rhythm Pharmaceuticals, Inc; Treatment of appetite and general nutrition disorders / Treatment of obesity and/or hyperphagia associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway

Day 30 discussion

Nutrition

3.1.27. Afatinib - EMEA-001596-PIP02-17

Treatment of oropharyngeal, laryngeal or nasal epithelial carcinoma, Treatment of paediatric patients with tumours with known ErbB deregulations irrespective of tumour histology, Treatment of lung carcinoma, Treatment of urether and bladder carcinoma / Treatment of paediatric patients aged between ≥ 1 year and ≤ 18 years with recurrent or refractory tumours with known ErbB deregulation and irrespective of tumour histology, -

Day 30 discussion

Oncology

3.1.28. Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide specific to the mRNA of the caspase 2 gene - EMEA-002224-PIP01-17

Treatment of optic nerve bleeding and vascular disorders / Treatment of ischaemic optic neuropathy

Day 30 discussion

Ophthalmology

3.1.29. Fosnetupitant / palonosetron - EMEA-001198-PIP03-17

Prevention of Chemotherapy-Induced Nausea and Vomiting

Day 30 discussion

Other

3.1.30. Sirolimus - Orphan - EMEA-002213-PIP01-17

Vascular Therapies, Inc.; Prevention of arteriovenous access dysfunction

Day 30 discussion

Other

3.1.31. EMEA-002160-PIP01-17

Prevention of human immunodeficiency virus (HIV-1) infection / Prevention of HIV-1 infection in children from 9 to less than 18 years of age

Day 30 discussion

Vaccines / Infectious Diseases

3.1.32. Clade C gp140 - EMEA-002221-PIP01-17

Prevention of human immunodeficiency virus (HIV-1) infection / Prevention of HIV-1 infection in children from 9 to less than 18 years of age

Day 30 discussion

Vaccines / Infectious Diseases

3.1.33. Mosaic gp140 / Clade C gp140 - EMEA-002161-PIP01-17

Prevention of human immunodeficiency virus (HIV-1) infection / Prevention of HIV-1 infection in children from 9 to less than 18 years of age

Day 30 discussion

Vaccines / Infectious Diseases

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.2.1. Avacopan - EMEA-C1-002023-PIP01-16-M01

ChemoCentryx, Ltd.; Treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.2.2. Mepolizumab - EMEA-C-000069-PIP02-10-M08

GSK TRADING SERVICES LIMITED; Treatment of asthma

Day 30 discussion

Pneumology - Allergology

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Recombinant human glutamic acid decarboxylase (rhGAD65) - EMEA-000609-PIP01-09-M01

Diamyd Medical AB; E10 Insulin-dependent diabetes mellitus / Treatment of type 1 Diabetes Mellitus of recent onset

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.2. Eluxadoline - EMEA-001579-PIP01-13-M02

Allergan Limited; Irritable bowel syndrome with diarrhoea

Day 30 discussion

Gastroenterology-Hepatology

3.3.3. Human coagulation factor X - Orphan - EMEA-000971-PIP01-10-M03

Bio Products Laboratory Limited; Treatment of hereditary factor X deficiency

Day 30 discussion

Haematology-Hemostaseology

3.3.4. Avacopan - Orphan - EMEA-002023-PIP01-16-M02

ChemoCentryx, Ltd.; Treatment of ANCA-associated vasculitis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.5. Human normal immunoglobulin for subcutaneous administration - EMEA-001853-PIP01-15-M01

Grifols Therapeutics Inc; Treatment for primary immunodeficiency

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.6. Bezlotoxumab - EMEA-001645-PIP01-14-M02

Merck Sharp & Dohme (Europe), Inc.; Treatment of Clostridium difficile infection / indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in paediatric patients at high risk for recurrence of CDI

Day 30 discussion

Infectious Diseases

3.3.7. Ataluren - Orphan - EMEA-000115-PIP01-07-M09

PTC Therapeutics International, Limited; Treatment of dystrophinopathy ICD-10: G71.0 Muscular dystrophy [of Duchenne and Becker] / Treatment of nonsense-mutation dystrophinopathy

Day 30 discussion

Neurology

3.3.8. Delta-9-tetrahydrocannabinol / Cannabidiol - EMEA-000181-PIP01-08-M04

GW Pharma Ltd; Spasticity / Intractable spasticity due to cerebral palsy or traumatic CNS injury

Day 30 discussion

Neurology

3.3.9. Blinatumomab - Orphan - EMEA-000574-PIP02-12-M02

Amgen Europe B.V.; Treatment of Acute Lymphoblastic Leukaemia / Treatment of Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL) in patients 1 month and older.

Day 30 discussion

Oncology

3.3.10. Ibrutinib - Orphan - EMEA-001397-PIP03-14-M03

Janssen-Cilag International N.V.; Treatment of mature B-cell neoplasms / Treatment of children from 1 year to less than 18 years of age with newly-diagnosed and relapsed/refractory mature B-cell lymphoma, that is, diffuse large B-cell lymphoma or Burkitt and Burkitt-like lymphoma.

Day 30 discussion

Oncology

3.3.11. Inotuzumb ozogamicin - Orphan - EMEA-001429-PIP01-13-M02

Pfizer Ltd; Treatment of Acute Lymphoblastic Leukaemia / For the treatment of relapsed or refractory B cell precursor Acute Lymphoblastic Leukaemia

Day 30 discussion

Oncology / Haematology-Hemostaseology

3.3.12. Human Thrombin / Human Fibrinogen - EMEA-001149-PIP01-11-M04

Omrix Biopharmaceuticals N.V.; Treatment of cerebrospinal fluid leakage resulting from a surgical procedure, Treatment of haemorrhage resulting from a surgical procedure / indicated for suture line sealing in dura mater closure indicated for supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis., indicated for supportive treatment in surgery where standard surgical techniques are insufficient, for improvement of haemostasis.

Day 30 discussion

Other

3.3.13. Lanadelumab - Orphan - EMEA-001864-PIP01-15-M01

Shire Pharmaceuticals Ireland Limited; Treatment of hereditary angioedema

Day 30 discussion

Other

3.3.14. Sildenafil - Orphan - EMEA-000671-PIP01-09-M09

Pfizer Limited; Treatment of Pulmonary Arterial Hypertension (PAH)

Day 30 discussion

Other

3.3.15. Spheroids of human autologous matrix-associated chondrocytes - EMEA-001264-PIP01-12-M01

CO.DON AG; Treatment of symptomatic articular cartilage defects of the femoral condyle and the patella of the knee (International Cartilage Repair Society [ICRS] grade III or IV) with defect sizes up to 10 cm2

Day 30 discussion

Other

3.3.16. Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) (1/5) each - EMEA-000794-PIP01-09-M01

LETI Pharma GmbH; J 30.1 Allergic rhinitis due to pollen, J 30.2 Other seasonal allergic rhinitis,, H10.1 Acute allergic conjunctivitis, J30.3 Other allergic rhinitis, J30.4 Allergic rhinitis, unspecified / Treatment of patients with allergic rhinitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family), Treatment of patients with allergic rhinoconjunctivitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family)

Day 30 discussion

Pneumology - Allergology

3.3.17. Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) and Secale cereale (Cultivated Rye) pollen (50/50) - EMEA-000792-PIP01-09-M01

LETI Pharma GmbH; J 30.1 Allergic rhinitis due to pollen, J 30.2 Other seasonal allergic rhinitis,, H10.1 Acute allergic conjunctivitis, J30.3 Other allergic rhinitis, J30.4 Allergic rhinitis, unspecified / Treatment of patients with allergic rhinitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family), Treatment of patients with allergic rhinoconjunctivitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family)

Day 30 discussion

Pneumology - Allergology

3.3.18. Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of Phleum pratense pollen - EMEA-000795-PIP01-09-M01

LETI Pharma GmbH; J 30.1 Allergic rhinitis due to pollen, J 30.2 Other seasonal allergic rhinitis,, H10.1 Acute allergic conjunctivitis, J30.3 Other allergic rhinitis, J30.4 Allergic rhinitis, unspecified / Treatment of patients with allergic rhinitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family), Treatment of patients with allergic rhinoconjunctivitis with or without intermittent allergic asthma due to sensitisation against grass pollens (Gramineas family)

Day 30 discussion

Pneumology - Allergology

4. Nominations

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 3 January 2018 for Nomination of Rapporteur and Peer reviewer

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

None

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6. Discussion on the applicability of class waivers

Disclosure of some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

6.1.1. Ribavirin - EMEA-16-2017

GlaxoSmithKline Intellectual Property Development Limited; All classes of medicinal products for treatment of chronic pulmonary obstructive disease (COPD)/ Reduction of the risk or severity of virally triggered COPD exacerbations in patients with COPD and a history of exacerbations

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was not confirmed as the medicinal

product is aimed to treat viral infections in patients with COPD and not COPD.

Note: The applications for marketing authorisation and or variation have to include a product-specific waiver or an agreement of a paediatric investigation plan in order to fulfil the requirements of Articles 7 and 8 of Regulation (EC) No 1901/2006.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

7.1.1. Rivaroxaban - EMEA-000430-PIP01-08-M10

Bayer AG; Prevention of thromboembolic events/ Prevention of stroke, myocardial infarction and cardiovascular death, and for the prevention of acute limb ischemia and mortality in adult patients with Coronary Artery Disease or Peripheral Artery Disease

Summary of committee discussion:

Rapporteur appointed. Discussion scheduled for November PDCO.

8. Annual reports on deferrals

Note: The annual reports on deferrals to be noted by the members of the PDCO are flagged in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

None

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

The list of procedures with paediatric indications to be evaluated by the CHMP, starting in September 2017 was presented to the PDCO members.

The members were also informed about 3 medicinal products, Firazyr, Stribild and Tasigna for which the CHMP adopted a positive opinion recommending a paediatric indication during their meeting in September 2017. A new pharmaceutical form (90, 180 and 360 mg granules), suitable for paediatric use, was approved for Exjade.

9.2.1.1. Joint CHMP/PDCO session

9.3. Coordination with EMA Working Parties / Working Groups / Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Karen Van Malderen

Summary of committee discussion:

The chair of the Non-clinical Working Group identified the products which will require Non-clinical Working Group evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

The chair of the Formulation Working Group identified the products which will require Formulation Working Group evaluation and discussion.

9.3.3. Reflection paper on the use of extrapolation in paediatric medicines development

PDCO member: Dirk Mentzer

Summary of committee discussion:

PDCO adopted the Reflection Paper for its public consultation release.

9.3.4. Minutes - PCWP/HCPWP joint meeting held on 27-28 June 2017

Summary of committee discussion:

Minutes were tabled for information.

9.3.5. Revision of the 'Guideline on recombinant and plasma-derived FVIII products'

Summary of committee discussion:

The Committee was informed about the status of this guideline.

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

Summary of committee discussion:

Two upcoming meetings of Enpr-EMA working groups (WG) were announced:

- Enpr-EMA WG on trial preparedness on 18 October 2017
- Enpr-EMA WG on ethics in collaboration with EUREC (European Network of Research Ethics Committees) on 13 November 2017

Moreover, the committee was informed that representatives of neonatal clinical trial networks have been invited to the PDCO's plenary meeting in November 2017.

9.5. Cooperation with International Regulators

9.5.1. ICH S11 and ICH S9 Questions and answers

PDCO Members: Karen van Malderen

Summary of committee discussion:

The PDCO had a brief discussion on the draft ICH S11 guideline and S9 Q&A.

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

None

9.7. PDCO work plan

9.7.1. Draft PDCO Work plan 2018

Summary of committee discussion:

The Committee discussed the first draft of the PDCO Work plan 2018.

9.8. Planning and reporting

9.8.1. Report on the International Paul Ehrlich Seminar - standard allergen PIP

Summary of committee discussion:

A short summary of the main discussions at the PEI symposium were presented to the PDCO.

At present, no long-term paediatric study as agreed in line with the requirements of the standard allergen PIP has been initiated. The results of the recently completed GAP (Grasaz asthma prevention study) provided first hints but no robust confirmation of a disease modifying effect. As such the committee agreed that in light of the rather small effect size on rhinitis and rescue medication use, the main benefit of immunotherapy would be on its potential long-term benefit in terms of disease modification that still has to be proved. The requirements of the standard PIP are still considered important, relevant and necessary.

Acknowledging the difficulties with conduct of such long-term paediatric studies and open scientific questions related to relevant endpoints, the committee agreed to start a new round of discussion and invite regulators of various NCA to discuss requirements for MAA for allergen products.

10. Any other business

10.1. AOB topic

10.1.1. Preparedness of the system and capacity increase

Summary of committee discussion:

The PDCO noted the update and next steps.

11. Breakout sessions

11.1.1. Paediatric oncology

Summary of committee discussion:

The working group discussed about the forthcoming 'paediatric strategy forum on medicine development for mature B cell malignancies in children', PIPs on targeted therapies

11.1.2. Neonatology

Summary of committee discussion:

The working group followed up on the discussion of neonatal topics at the recent Strategic Review and Learning Meeting (SRLM) held in Tallinn on 4-6 October, particularly on how the group can best provide input into ongoing procedures that impact neonates.

11.1.3. Inventory

Summary of committee discussion:

The inventory group followed up on the discussion on paediatric unmet needs at the recent Strategic Review and Learning Meeting (SRLM) held in Tallinn on 4-6 October.

12. List of participants

List of participants including any restrictions with respect to involvement of members/alternates/ experts following evaluation of declared interests for the 10 – 13 October 2017 meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dirk Mentzer	Chair	Germany	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Johanna Wernsperger	Alternate	Austria	No interests declared	
Koenraad Norga	Member (Vice-Chair)	Belgium	When chairing the meeting: To be replaced for discussions, final deliberations and voting When not chairing the meeting: No participation in final deliberations and voting	EMEA-C-000069-PIP02-10-M08 EMEA-16-2017
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Adriana Andrić	Member	Croatia	No interests declared	
Suzana Mimica Matanovic	Alternate	Croatia	No interests declared	
Jaroslav Sterba	Member	Czech Republic	No interests declared	
Peter Szitanyi	Alternate	Czech Republic	No interests declared	
Marianne Orholm	Member	Denmark	No interests declared	
Kirstine Moll Harboe	Alternate	Denmark	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Ann Marie Kaukonen	Member	Finland	No interests declared	
Sylvie Benchetrit	Member	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Immanuel Barth	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Alessandro Jenkner	Alternate	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No interests declared	
Goda Vaitkeviciene	Alternate	Lithuania	No interests declared	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Maaike van Dartel	Member	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Marek Migdal	Member	Poland	No interests declared	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesús Fernández Cortizo	Alternate	Spain	No interests declared	
Ninna Gullberg	Member	Sweden	No interests declared	
Eva Agurell	Alternate	Sweden	No restrictions applicable to this meeting	
Angeliki Siapkara	Member	United Kingdom	No interests declared	
Martina Riegl	Alternate	United Kingdom	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No interests declared	
Riccardo Riccardi	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Doina Plesca	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Günter Karl-Heinz Auerswald	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared	
Sara Homer	Expert - in person*	United Kingdom	No interests declared	
Juliana Min	Expert - in	United Kingdom	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
	person*			
Eleni Gaki	Expert - in person*	United Kingdom	No interests declared	
Meeting run with support from relevant EMA staff				

* Experts were only evaluated against the product(s) they have been invited to talk about.

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/